ReviewBest practice & research. Clinical rheumatology2021
Managing patients using telerheumatology: Lessons from a pandemic.
Review in Best practice & research. Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Facilitators of and Barriers to Accessing Hospital Medical Specialty Telemedicine Consultations During the COVID-19 Pandemic: Systematic Review.Journal of medical Internet research · 2023Pooled it
- Home-Based Telemedicine in Rheumatology-A Scoping Review.ACR open rheumatology · 2024Article
- Key data elements for a successful pediatric rheumatology virtual visit: a survey within the PR-COIN network.Frontiers in pediatrics · 2024Article
- Behcet's intestinal disease confirmation: telemedicine images demonstrating stomal ulceration facilitate prompt assessment.Clinical rheumatology · 2023Article
- Article
- The impact of the COVID-19 pandemic and stringent social distancing measures on health-related quality of life and COVID-19 infection rates in patients with rheumatic disease: a longitudinal analysis through the pandemic.Rheumatology advances in practice · 2023Article
- Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic.Lupus science & medicine · 2022Article
- Why do we fall short in reaching equity in telerheumatology?Health policy and technology · 2022Article
- The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life.Clinical rheumatology · 2022Review
- Experience with telemedicine among rheumatology clinicians during the COVID-19 pandemic: an international survey.Rheumatology advances in practice · 2022Article
- Lessons from experiences of accessing healthcare during the pandemic for remobilizing rheumatology services: a national mixed methods study.Rheumatology advances in practice · 2022Article
- Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry.Rheumatology international · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has presented unique challenges to rheumatology provision. Measures to control the pandemic have limited face-to-face contact with rheumatology healthcare professionals. One innovation has been the widespread adoption of telerheumatology to assist in the care of patients with rheumatic and musculoskeletal diseases, building on an existing evidence base in rheumatology. Widespread adoption has only occurred following the COVID-19 pandemic. We discuss the evidence supporting telerheumatology adoption prior to the pandemic, and outline several innovative approaches used to assist in the care of rheumatology patients that have been introduced. Alongside the advantages of these interventions, we discuss the limitations and regulatory challenges. Advances must be balanced, considering wider issues of equity of access, implementation, adoption, and sustainability of telerheumatology post-pandemic. We propose it is not 'if', but 'how' rheumatologists embrace newer telerheumatology technology, outlining practice points and future research agenda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.